Aligos Therapeutics, Inc. (ALGS)
 NASDAQ: ALGS · Real-Time Price · USD
 7.53
 -0.72 (-8.73%)
  At close: Nov 3, 2025, 4:00 PM EST
7.68
 +0.15 (1.99%)
  After-hours: Nov 3, 2025, 6:19 PM EST
Aligos Therapeutics Employees
Aligos Therapeutics had 70 employees as of December 31, 2024. The number of employees increased by 4 or 6.06% compared to the previous year.
Employees 
 70
Change (1Y) 
 4
Growth (1Y) 
 6.06%
Revenue / Employee 
 $45,343
Profits / Employee 
 -$1,059,771
Market Cap 
46.32M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 70 | 4 | 6.06% | 
| Dec 31, 2023 | 66 | -17 | -20.48% | 
| Dec 31, 2022 | 83 | -10 | -10.75% | 
| Dec 31, 2021 | 93 | 19 | 25.68% | 
| Dec 31, 2020 | 74 | 13 | 21.31% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
ALGS News
- 4 days ago - Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025 - GlobeNewsWire
 - 17 days ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
 - 18 days ago - Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184 - GlobeNewsWire
 - 20 days ago - Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference - GlobeNewsWire
 - 27 days ago - Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 - GlobeNewsWire
 - 2 months ago - Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting - GlobeNewsWire
 - 2 months ago - Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
 - 2 months ago - Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs - GlobeNewsWire